Document is current
Any future updates will be listed below
-
Authors
Daneshmandi, Saeed
Yan, Qi
Choi, Jee Eun
Katsuta, Eriko https://orcid.org/0000-0001-5862-2919
MacDonald, Cameron R.
Goruganthu, Mounika
Roberts, Nathan
Repasky, Elizabeth A.
Singh, Prashant K.
Attwood, Kristopher
Wang, Jianmin https://orcid.org/0000-0001-7527-0409
Landesman, Yosef
McCarthy, Philip L. https://orcid.org/0000-0002-9577-3879
Mohammadpour, Hemn https://orcid.org/0000-0002-0158-7283
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R00HL155792)
- License Information
-
More Information
Article History
Received: 17 October 2023
Accepted: 14 May 2024
First Online: 20 June 2024
Competing interests
: Advisory Board/Consulting for P.L.M.: BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, and Takeda. Honoraria for P.L.M.: BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, and Takeda. Employment for Y.L.: Karyopharm.
